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ABSTRACT
Cryptic splice sites are used only when use of a
natural splice site is disrupted by mutation. To
determine the features that distinguish authentic
from cryptic 5¢ splice sites (5¢ss), we systematically
analyzed a set of 76 cryptic 5¢ss derived from 46
human genes. These cryptic 5¢ss have a similar
frequency distribution in exons and introns, and
are usually located close to the authentic 5¢ss.
Statistical analysis of the strengths of the 5¢ss using
the Shapiro and Senapathy matrix revealed that
authentic 5¢ss have signi®cantly higher score values
than cryptic 5¢ss, which in turn have higher values
than the mutant ones. b-Globin provides an interest-
ing exception to this rule, so we chose it for detailed
experimental analysis in vitro. We found that the
sequences of the b-globin authentic and cryptic
5¢ss, but not their surrounding context, determine
the correct 5¢ss choice, although their respective
scores do not re¯ect this functional difference. Our
analysis provides a statistical basis to explain the
competitive advantage of authentic over cryptic 5¢ss
in most cases, and should facilitate the develop-
ment of tools to reliably predict the effect of
disease-associated 5¢ss-disrupting mutations at the
mRNA level.
INTRODUCTION
Accurate splicing of pre-mRNA is a critical step in the gene
expression pathway in eukaryotes. The exon±intron boun-
daries, known as the 5¢ and 3¢ splice sites, are de®ned by
conserved sequences that are critical for the reaction. Because
the splice-site consensus motifs are degenerate, many matches
to each consensus are present along pre-mRNAs, but the vast
majority of these sequences, known as pseudo splice sites, are
never selected for splicing (1). Cryptic splice sites also match
the consensus motifs, and by de®nition they are splice sites
that are not detectably used in wild-type pre-mRNA, but are
only selected as a result of a mutation elsewhere in the gene,
most often at the authentic splice site.
The 5¢ splice site (5¢ss) consensus sequence in higher
eukaryotes comprises nine partially conserved nucleotides at
the exon±intron boundary, and corresponds to nearly perfect
Watson±Crick base pairing to the U1 snRNA 5¢ terminus (2).
There is strong genetic and biochemical evidence for the
critical contribution of this base pairing to selection of the 5¢ss
(3±5). However, U1 snRNA appears to be dispensable for
splicing of some pre-mRNAs; in such cases, U6 snRNA and
SR proteins can make up for the absence of functional U1
snRNA in depleted extracts (6±8). In vitro selection of
functional 5¢ss sequences surprisingly yielded the same
consensus sequence in splicing reactions containing either
wild-type or 5¢-end-deleted human U1 snRNAs (9). Consistent
with this ®nding, yeast U1 snRNP can still bind to a 5¢ss in the
absence of the 5¢ end of U1 snRNA (10), and it has been
proposed that the U1C polypeptide is responsible for this
interaction (11). In addition, U1 snRNP binding to a 5¢ss is not
always followed by splicing at that site, as several U1
particles can simultaneously base pair to competing 5¢ss,
even when only one of the sites is selected for splicing (12).
After the initial recognition of the 5¢ss by U1, U5 and U6
snRNPs also bind at or around the 5¢ss. U6 snRNA base pairs
to the 5¢ss in a mutually exclusive manner with U1 snRNA
(13), and likely participates in splicing catalysis. However, U1
and U6 snRNAs can bind to adjacent, non-overlapping
sequences of a pre-mRNA, and in this case the actual site of
transesteri®cation is de®ned by U6 snRNA (14,15).
Insights into the mechanisms of cryptic splice-site activ-
ation have been obtained experimentally in several systems.
Thalassemia-associated mutations of the 5¢ss of intron 1 of the
human b-globin gene, Hbb, activate the use of three cryptic
5¢ss, upstream and downstream of the natural site (16). Co-
immunoprecipitation of wild-type and mutant b-globin sub-
strates with U1 snRNP antibodies, combined with RNase T1
digestion, revealed differences between these sequences in
their apparent af®nities for U1 (17). Furthermore, mutations in
a b-globin exon 1 cryptic 5¢ss at position ±38 that enhance
complementarity to U1 snRNA activate this splice site in the
presence of a wild-type authentic 5¢ss (18). Increasing the
levels of SR proteins or hnRNP A/B proteins affects the
relative use of each of the three cryptic splice sites in mutant
substrates, both in vitro and in transfected cells (19±21).
However, in no case was a shift in splice-site usage seen with
the wild-type b-globin pre-mRNA, indicating that an excess of
these splicing factors does not abrogate the distinction
between authentic and cryptic 5¢ss. Experiments with an
adenovirus pre-mRNA showed that the use of a cryptic 5¢ss
depends on secondary structure in the upstream exon, and that
the kinetics of splicing via the cryptic site is slower than that
via the authentic site (22). A genetic screen in Caenorhabditis
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elegans unveiled a dominant, allele-speci®c suppressor muta-
tion in sup-39 that affects the choice among two cryptic 5¢ss
and a mutant 5¢ss in unc-73(e936), such that use of the mutant
5¢ss is favored (23,24); the sup-39 gene remains to be
identi®ed, so it is not yet known whether it encodes a protein
or an RNA. U snRNA complementation experiments in
Saccharomyces cerevisiae revealed that both U5 (25) and U6
snRNAs (26) are involved in cryptic 5¢ss activation in yeast,
and recent experiments in Schizosaccharomyces pombe also
showed that mutant versions of U1 can activate cryptic 5¢ss
(27). Finally, Eperon and colleagues carried out a competition
analysis between different 5¢ss sequences, and found that the
three cryptic 5¢ss they analyzed competed poorly in relation to
authentic and alternative 5¢ss (28).
Point mutations resulting in splicing defects account for at
least 15% (29) and in some cases as many as 50% of known
alleles in human-disease genes (30,31). In higher eukaryotes,
mutations that disrupt a 5¢ss usually cause skipping of the exon
that precedes it (32). The second most frequent consequence
of such mutations is cryptic splice-site activation, whereas
intron retention is very rare. Most reported splicing mutations
in mutation databases have been described only at the genomic
sequence level, and their effect at the protein level cannot be
accurately predicted because it depends on which of these
three splicing pathways are followed as a consequence of the
mutation.
The latest compilation that includes cryptic 5¢ss is the
Aberrant Splicing Database, published in 1994, with 28
cryptic 5¢ss and 15 cryptic 3¢ss from different mammalian
species (32). The aim of our study was to determine the
general nature of the differences between authentic 5¢ss and
the corresponding cryptic 5¢ss that are activated upon muta-
tion. We addressed this question by compiling available
examples of cryptic 5¢ss in human genes, building a database,
and analyzing the various splice sites by statistical methods.
One particular case, derived from b-globin, was chosen for
experimental analysis of the mechanism of cryptic 5¢ss
repression and activation. We show that, as a general rule,
the extreme difference in splicing ef®ciency between com-
peting authentic and cryptic 5¢ss is determined by the
sequences of the 9 nt 5¢ss motifs.
MATERIALS AND METHODS
Construction of the database
Published examples of cryptic 5¢ss activation were identi®ed
by searching PubMed (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi). We restricted the search to human genes, to avoid
potential species-speci®c variability. We only included
experimentally veri®ed cryptic 5¢ss. A few examples of
cryptic 5¢ss activation were omitted from the compilation
because the genomic DNA sequence could not be located in
the most recent release of the HGP database. The accessions
were mapped to the genome using software we developed.
Automatic corrections were made to ensure that the exon±
intron boundaries were in the appropriate locations. Manual
curation was used to improve the software and check the
mapping results. The cryptic 5¢ss were then mapped to the
sequences using information from the references.
We also collected human alternative 5¢ss extracted from the
ASAP database (33). We chose only alternative 5¢ss that were
labeled with high con®dence as tissue speci®c. To ensure that
the pool included only 5¢ss that result from true alternative
splicing events, we used the ASAP tools to select the
alternative 5¢ss supported by mRNA sequences, or by a
minimum of seven ESTs, or two or more ESTs with different
splicing patterns. 230 alternative 5¢ss in ASAP met all these
criteria (see the online supplement).
Statistical tests
To measure the strengths of the various 5¢ss, we used the
Shapiro and Senapathy (S&S) consensus matrix, which
re¯ects the degree of conservation in different positions
resulting from the alignment of 1446 5¢ss (34,35). The
consensus 5¢ss sequence is MAG|GURAGU (M = A or C;
R = purine), and spans from position ±3 (the third nucleotide
from the 3¢ end of the upstream exon) to +6 (the sixth
nucleotide in the intron). Although position ±3 is often ignored
in these matrices, we took it into account because of the
signi®cant preference for C or A at this position.
The S&S scores for the different kinds of 5¢ss (authentic,
cryptic, mutant, pseudo and alternative) are not distributed
normally around their means. Therefore, we used non-
parametric tests to assess the signi®cance of the score values
for the ®ve classes of 5¢ss. To test the signi®cance of deviation
from zero of the difference between pairs of scores, we used
the Wilcoxon signed rank test; to test the signi®cance of the
deviation of the overall means from each other for the
different classes of 5¢ss, we used the Mann±Whitney rank test.
The pairwise analysis involves a case-by-case evaluation of
the intrinsic differences between corresponding 5¢ss associ-
ated with the same exon, and re¯ects the natural context in
which splice-site selection occurs.
To calculate the free-energy parameters for the stability of
the RNA duplexes between the various 5¢ss sequences and the
U1 snRNA 5¢ terminus, we used the Turner energy rules as
described in http://www.bioinfo.rpi.edu/~zukerm/rna/energy/
(11/3/2000 update). These rules are based on measurements
with synthetic oligoribonucleotides and re¯ect the contribu-
tion of hydrogen bonding, base stacking, mismatches and
Watson±Crick or G±U base pairs (36).
Cloning procedures
All b-globin substrates were inserted into a pcDNA3.1+
plasmid (Invitrogen, Carlsbad, CA), and all bear a mutation of
the cryptic 5¢ss at position +13Ða T to C transition at +14Ð
that inactivates this 5¢ss. For the mutants in Figure 4B, we used
site-directed mutagenesis with oligonucleotides that carry the
different mutations. For each pair of primers, 16 cycles of PCR
with Pfu I Turbo (Stratagene) were performed. PCR products
were digested with DpnI (New England Biolabs, Beverly,
MA), followed by transformation of competent Escherichia
coli DH5a. The following mutations were introduced: (i) a
mutation of the authentic 5¢ss at +1: CAG/AACCCG; (ii) a
duplication of the authentic 5¢ss CAG/GTTGGT at positions
±16 and +1; (iii) a duplication of the cryptic 5¢ss at ±16 GTG/
GTGAGG at positions ±16 and +1; and (iv) a swap of
sequences between the 5¢ss at ±16 and +1. All mutant
constructs were veri®ed by sequencing on an ABI3700
Automated Sequencer.
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In vitro splicing experiments
Human b-globin templates were made by PCR using the
following primers: b-5-T7, 5¢-AATTTAATACGACTCACT-
ATAGGCTTACATTTGCTTCTG-3¢; and R-Ex2-Bam-txn,
5¢-GATCCACGTGCAGCTTGTCACAGTG-3¢. The products
were puri®ed with a PCR-puri®cation kit (Qiagen, Valencia,
CA). Capped, 32P-labeled pre-mRNA substrates were tran-
scribed from puri®ed PCR products with T7 RNA polymerase
(Promega, Madison, WI) and gel puri®ed (37).
HeLa cell nuclear extract preparation and splicing reactions
were carried out as described (37,38). For in vitro splicing
reactions, 20 fmol of 32P-labeled, 7CH3-GpppG-capped T7
transcripts were incubated in 12.5 ml splicing reactions with
30% nuclear extract and 3.2 mM MgCl2, for 3 h at 30°C.
Samples were analyzed by electrophoresis on 5.5% poly-
acrylamide/7 M urea gels. Gels were exposed overnight onto
X-OMAT ®lms (Kodak).
RESULTS
A compilation of human cryptic 5¢ss
Table 1 shows all the cases of cryptic splicing in human genes
included in the present analysis. Cryptic 5¢ss are those that are
only used when a mutation disrupts use of the authentic splice
site. Note that cryptic splice sites differ from splice sites that
are created de novo by a mutation in an exon or intron that
increases the match to a splice-site consensus. However, use of
such a created splice site can frequently occur in conjunction
with activation of a cryptic splice site, such that, e.g. a created
5¢ss and an activated cryptic 3¢ splice site upstream together
de®ne a new exon. Figure 1 shows an example of cryptic 5¢ss
activation in the porphobilinogen deaminase (PBGD) gene
(39), associated with acute intermittent porphyria. In this case,
a mutation in the last nucleotide of exon 10 activates a cryptic
5¢ss (C) 9 nt upstream of the mutant 5¢ss (M), whereas other
good matches to the 5¢ss consensus around this area are never
used, so they are considered pseudo 5¢ss (P). We found 76
reported examples of cryptic 5¢ss in 46 human genes, and this
sample size enables meaningful statistical tests to be con-
ducted. Mutations that activate cryptic 5¢ss mapped to the
authentic 5¢ss sequence, with one exception in the COL7A1
gene (40), in which a 28 bp genomic deletion in the middle of
exon 73 activates use of a cryptic 5¢ss 10 nt downstream of the
deletion. In all but two cases (41,42), the mutation is
associated with a genetic disease, i.e. hereditary syndromes
and/or cancer.
General features of cryptic 5¢ss
Table 2 summarizes the general features of the splice sites we
analyzed. The cryptic 5¢ss were found with equal frequencies
in exons and introns; they were found both in ®rst exons
(seven out of 61 exons) and in internal exons. The cryptic 5¢ss
did not show a bias towards a particular reading-frame phase,
relative to that established by the position of the authentic 5¢ss
(Table 2). Forty two percent of the cryptic 5¢ss were in the
same reading frame as the authentic 5¢ss, i.e. the distance
between the authentic and cryptic splice sites was a multiple of
three nucleotides; 32% were shifted by +1 nucleotide and 26%
were shifted by +2 nucleotides. These frequencies are not
appreciably different from a random distribution.
The observed distribution of distances between authentic
and cryptic 5¢ss resembles a normal distribution with its peak
centered at position +11 (Fig. 2a). The observed absolute
average distance (63 nt) and its large standard deviation (SD)
(64 nt) correspond to a broad-range distribution, spanning
from ±141 in the exon to +398 in the intron (Table 2). This
distribution indicates that cryptic 5¢ss can in a few cases be
located very far from the original site, even when the size of
the resulting exon becomes sub-optimally small or large. The
distribution is not completely symmetrical because the density
of cryptic 5¢ss located in the upstream exon is slightly higher
around the authentic site than that of the cryptic 5¢ss in the
downstream intron (Fig. 2b).
In general, the length of the abnormal exons that result from
cryptic 5¢ss usage is within the range for most internal exons
[between 50 and 250 nt (43)]: out of 54 internal exons
(average length 159 nt) whose 5¢ss disruption leads to cryptic
5¢ss activation, eight (15%) are beyond these limits; out of 64
internal exons (average length 174 nt) that result from cryptic
5¢ss activation, 14 (22%) are beyond these length constraints
(Table 2).
Recently, it was reported that in-frame stop codons located
between an authentic 5¢ss and a downstream latent or
alternative 5¢ss favor the use of the upstream 5¢ss (44). In
contrast, a subsequent study found no enrichment of in-frame
stop codons in pseudo-exons (intronic sequences ¯anked by
strong splice sites), or in intronic regions immediately
downstream of exons (45). We analyzed the presence of in-
frame stop codons between authentic and cryptic 5¢ss, when
the latter are located within the downstream intron. Of 39
intronic cryptic 5¢ss in 27 genes, only half (19 cryptic 5¢ss)
were preceded by in-frame stop codons. The numbers do not
enable statistical tests, but there does not appear to be an
enrichment of stop codons between authentic and cryptic 5¢ss
in this data set that would account for the correct speci®cation
of the upstream authentic sites in the wild-type pre-mRNAs.
Analysis of the consensus value of the 5¢ss by the
Shapiro and Senapathy matrix
Table 3 shows a comparison of the S&S consensus values
(34,35) for the ®ve types of 5¢ss: authentic, cryptic, mutant,
pseudo and alternative 5¢ss. The mutant category refers to
mutated versions of an authentic 5¢ss, which affect the
ef®ciency of splicing at that site. To construct a set of
reference pseudo 5¢ss relevant for this analysis, we chose all
the sequences in the Table 1 gene set with S&S scores above a
threshold arbitrarily set at 60 (which detects >90% of the
cryptic 5¢ss), and located closer to the authentic 5¢ssÐon
either side of itÐthan the cryptic 5¢ss. Figure 3 displays the
average and SD of the S&S scores for each category of 5¢ss
(Fig. 3A), and the differences in the scores for each pair of 5¢ss
that occurs in the same pre-mRNA (Fig. 3B). The average
S&S score of cryptic 5¢ss located in exons is very similar to the
average score of the cryptic 5¢ss in introns (71.01 versus
73.69).
By comparing the authentic and mutant groups, it is clear
that the differences between the wild-type 5¢ss and the mutant
versions are very signi®cant, both in comparisons of the sets of
sequences and of pairs of sequences in the same gene, as seen
in previous studies (29,30). Indeed, in nearly all cases, the
mutation of the 5¢ss decreases the S&S score. There is only
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Table 1. Data set of cryptic 5¢ss in human genes
Gene Disease/defect Mutation Position of cryptic 5¢ssa Reference
ABCD1 X-linked adrenoleukodystrophy (X-ALD) IVS1 G(±1)A IVS1 +10 65
APOB Homozygous hypobetalipoproteinemia IVS24 T2C IVS24 +41 66
AR Androgen insensitivity IVS4 G1T Exon4 ±123 67
ATM Ataxia-telangiectasia IVS45 G1A IVS45 +72, +80 31
BRCA1 Breast cancer IVS5 A(±2)G Exon5 ±22 68
IVS16 T6C IVS16 +70 69
CFTR Cystic ®brosis IVS20 G(±1)C IVS20 +30 70
IVS4 G1T Exon4 ±93 49
COL1A1 Severe type III osteogenesis imperfecta Exon34 del[±3:IVS36+X] Exon34 ±8 71
IVS8 G1A IVS8 G +97/exon 8 ±26 72
IVS8 G5A IVS8 +97 73
COL3A1 Ehlers-Danlos syndrome IV IVS16 G1A IVS16 +24 50
IVS20 G1A IVS20 +25 50
IVS42 G1A IVS42 +31 50
COL6A1 Mild Bethlem myopathy IVS3 G1A Exon3 ±66 74
COL7A1 Recessive dystrophic epidermolysis bullosa IVS3 A(±2)G Exon 3 ±104 46
IVS95 G(±1)A Exon95 ±7 46
Dominant dystrophic epidermolysis bullosa Exon73 del[±98: ±71] Exon73 ±62 40
C3 Hereditary C3 de®ciency IVS18 G1A Exon18 ±61 75
CYP19 Placental aromatase de®ciency IVS6 T2C IVS6 +88 76
CYP27A1 Cerebrotendinous xanthomatosis IVS6 C(±2)A/G(±1)A Exon6 ±89 77
DMD Duchenne and Becker muscular dystrophy IVS64 G5C IVS64 +58 78
IVS26 T2G IVS26 +117 79
FAH Chronic tyrosinemia type I IVS12 G5A IVS112 +106 80
FBN1 Marfan syndrome IVS46 G1A IVS46 +34 81
F5 Severe factor V de®ciency IVS10 G(±1)T Exon10 ±35 82
FGA Common congenital a®brinogenemia IVS4 G1T IVS4 +5/exon4 ±1, ±66, ±36 83
F7 FVII de®ciency IVS7 G5A/A7G/del[+3:+6] IVS7 +38 51
GCK Maturity onset diabetes of the young (MODY) IVS4 del[+2:+16] Exon4 ±24 84
GHV Mutation in placenta IVS2 G1A IVS2 +13 42
HBA2 Alpha-thalassemia IVS1 del[+2:+6] Exon1 ±49 85
HBB Beta-thalassemia IVS1 G(±1)C/G1A/G1T/T2C/G5A/
G5C/G5T/T6C
Exon1 ±38, ±16/IVS1 +13 16
IVS2 del[+4:+5] Exon2 ±135/ IVS2 +48 32
HEXA Tay-Sachs syndrome IVS9 G1A IVS9 +18 86
HEXB Sandhoff disease IVS8 G5C Exon8 ±4 52
HMGCL Hereditary HL de®ciency IVS 7 IVS7 +79 87
HPRT1 Somatic mutations in kidney tubular epithelial cells IVS1 G5A/G5T/del[-2:+34] IVS1 +50 41
Lesch-Nyhan syndrome IVS5 T2G/AA3:4GT/G5A/del[G1] IVS5 +68 88
IDS Mucopolysaccharidosis type II (Hunter syndrome) IVS7 GG[±1:+1]TT IVS7 +23 89
ITGB2 Leukocyte adhesion de®ciency IVS7 G1A IVS7 +65,+299 90
ITGB3 Glanzmann thrombasthenia IVS4 G1A IVS4 +28 91
KRT5 Dowling-Meara epidermolysis bullosa simplex IVS1 G1A Exon1 ±66 92
LDLR Familial hypercholesterolemia IVS12 T2C IVS12 +12 53
LPL Familial hypercholesterolemia IVS2 G1A Exon2 ±18/IVS2 +43, +143,
+247, +383
54
MTHFR Severe de®ciency of MTHFR IVS4 G1A Exon4 ±57 93
NF1 Neuro®bromatosis type I IVS27b del[+1:+10] Exon27b ±69 30
IVS28 G1A Exon28 ±54 30
NF2 Neuro®bromatosis type II IVS7 G5A/del[±3:+11] Exon7 ±23, ±28 94
IVS12 G1A/del[±14:+2] Exon12 ±38, ±53 94
PBGD Acute intermittent porphyria IVS1 G1A/T2A/G5C/G3T IVS1 +68 95
IVS10 G(±1)T Exon 10 ±9 39
PGK1 Phosphoglycerate kinase de®ciency IVS4 G1T IVS4 +31 96
PKD1 Polycystic kidney disease 1 IVS43 Exon43 ±66 97
PTEN Cowden syndrome IVS7 G1A IVS7 +76 98
IVS4 T2C IVS4 +5 98
PYGM Myophosphorylase de®ciency (McArdle disease) IVS14 G1A Exon14 ±67 99
RPGR X-linked retinitis pigmentosa (RP3) IVS5 G1T Exon5 ±76 100
SERPINA1 Risk for emphysema IVS2 G1T Exon2 ±84 101
TP53 Colorectal tumors IVS5 G5C Exon5 ±46 102
Squamous cell carcinoma IVS6 G(±1)A/G1A IVS6 +6 103
TSC2 Familial tuberous sclerosis IVS37 ins[+2A] Exon37 ±29 104
UGT1A1 Crigler-Najjar syndrome type 1 IVS1 G1C Exon1 ±141 105
46 genes 76 cryptic 5¢ss
IVS, intervening sequence or intron.
aPosition relative to the authentic 5¢ss; positive numbers towards the downstream intron, negative numbers towards the upstream exon.
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one reported exception, in the COL7A1 gene, in which an A to
G transition at position ±2 of the 5¢ss of intron 3 improved the
S&S score, but nevertheless reduced splicing at that site (46).
Likewise, the group and pairwise comparisons between the
cryptic and mutant 5¢ss gave consistent results. The S&S
scores of the cryptic 5¢ss are signi®cantly higher than those of
the mutant 5¢ss. This higher score value is consistent with the
activation of the cryptic 5¢ss in the context of mutant pre-
mRNAs. It should be noted that not all these mutations
completely abolish splicing at the authentic 5¢ss, but all do
reduce the ef®ciency of the reaction at that site.
Most interestingly, both the group and pairwise compari-
sons of the S&S scores between authentic and cryptic 5¢ss
showed that the latter values are signi®cantly lower. Thus, as a
general rule, intrinsic differences in the 9 nt consensus 5¢ss
sequence can account for the cryptic 5¢ss remaining com-
pletely silent in the presence of a wild-type authentic site.
For comparison, we also included a set of 230 alternative
5¢ss extracted from the ASAP database (33). The average S&S
score for this alternative 5¢ss data set is 78.26 (Fig. 3 and
Table 3), i.e. between the averages of authentic and cryptic
5¢ss, but closer to the former. Statistical comparisons between
the S&S scores of alternative and those of cryptic, mutant and
pseudo 5¢ss show that the alternative 5¢ss have signi®cantly
higher scores than those of the latter three categories (Table 3
and data not shown). The S&S scores of authentic 5¢ss, in turn,
are also signi®cantly higher than those of alternative 5¢ss,
although the difference of averages of the two kinds of scores
is only 4.7.
Next, we calculated the potential matches to the 5¢ss
consensus that have an S&S score above a threshold of 60, and
that are located closest to a given authentic 5¢ss. This threshold
was arbitrarily chosen instead of the lowest score of the cryptic
5¢ss (49.73), to exclude many potential 5¢ss with very low
scores. These potential 5¢ss were compared with the total pool
of cryptic 5¢ss. Although ®ve of the cryptic 5¢ss have an S&S
score lower than 60, eliminating them from the analysis did
not signi®cantly alter the results (data not shown). Of 61
different exons in which one or more cryptic 5¢ss are activated
when the authentic splice site is disrupted (Table 1), in 35
cases the closest potential site coincides with the cryptic 5¢ss,
or with one of several cryptic 5¢ss. This observation suggests
that the cryptic 5¢ss(s) activated when a mutation inactivates
or weakens an authentic 5¢ss is usually the nearest sequence
with a good match to the S&S consensus. However, in seven
of the 35 cases, other cryptic 5¢ss located further in the exon or
in the intron are also activated.
The remaining 26 cases, in which the closest potential 5¢ss
does not coincide with the cryptic 5¢ss, were considered
pseudo 5¢ss. To increase the number of samples, we also
included the second spatially closest match to the S&S
consensus that is not also a cryptic 5¢ss. The S&S scores of
these pseudo sites are signi®cantly lower than the scores of the
authentic sites. According to the above hypothetical rule, a
pseudo site located between an authentic site and a cryptic site
should have a lower S&S score than the cryptic site. However,
although the mean value for the cryptic sites is higher than that
for the pseudo sites, the difference is only marginally
signi®cant. The pairwise comparison failed to show statistic-
ally signi®cant differences. This result argues against the
simple model that, given a genomic sequence, one can reliably
predict which potential 5¢ss will act as a cryptic 5¢ss when the
authentic site is mutated.
We also calculated the strength of base pairing between the
various categories of 5¢ss and the U1 snRNA 5¢ terminus (see
Supplementary Material). Although the differences observed
using the S&S matrix were also seen using the calculated
Figure 1. Diagram of a portion of the human porphobilinogen deaminase (PBGD) gene, spanning exons 10±11. Gray boxes and uppercase letters represent
exons 10 and 11, and lowercase letters and line represent intron 10. The two possible splicing patterns, by use of an authentic 5¢ss (A arrow) or a cryptic 5¢ss
(C arrow) in exon 10 are represented above and below the sequences, respectively. The latter pathway is only seen when the authentic 5¢ss is disrupted by a
mutation (M arrow), such as G to T transversion at position ±1 (39). Also shown are two pseudo 5¢ss (P arrows), i.e. sequences that match the 5¢ss consensus
but are not functional in either the wild-type or mutant contexts.
Table 2. Summary of cryptic 5¢ss properties
Number of genes 46
Number of cryptic 5¢ss 76
In exons 37 (49%)
In introns 39 (51%)
Reading frame (C relative to A)a
0 32 (42%) Chi-square (2) = 2.42,
I 24 (32%) P = 0.30
II 20 (26%)
Distance of C to A (nt) Average SD
Allb 10.92 88.93
Absolute 62.58 63.73
Exonic C 53.05 35.92
Exonic C (internal)c 51.66 34.49
Intronic C 71.62 81.37
Intronic C (internal)c 75.86 84.55
Exon length A 200.03 217.44
Exon length A (internal)c 160.22 98.88
Exon length C 201.58 195.18
Exon length C (internal)c 174.21 111.56
Closest C (to A) ±4, +4
Range ±141 to +398
aC, cryptic 5¢ss; A, authentic 5¢ss.
bConsidering positive distances for C within introns, and negative distances
for C within exons.
cAssociated with internal exons only.
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base-pairing measure, there were more exceptions in the
comparison between authentic and cryptic 5¢ss: 21 cryptic 5¢ss
(28%) had a higher predicted U1 base-pairing stability than
their corresponding authentic 5¢ss. In only nine of these cases
(and four others), the S&S score of the cryptic 5¢ss was higher
than that of the corresponding authentic 5¢ss. This comparison
suggests that discrimination between authentic and cryptic
5¢ss might be explained by differential duplex stability with
U1 snRNA in some of the samples, but not in all.
The strengths of the authentic and cryptic 5¢ss were also
calculated by four other methods (Table 4): the neural network
(NN) method (47) (http://www.fruit¯y.org/seq_tools/splice.
html), and the maximum entropy (MAXENT), maximum
dependence decomposition (MDD) and ®rst-order Markov
(MM) models (48) (http://genes.mit.edu/burgelab/maxent/
Xmaxentscan_scoreseq.html). The number of exceptions to
the competitive advantage of authentic versus cryptic 5¢ss
varied among them, with NN and MDD being the best
discriminators between these 5¢ss (six exceptions for each
method), and the free-energy parameter model being the least
accurate (21 exceptions). Of the 76 cryptic 5¢ss, only three
gave higher scores than their corresponding authentic 5¢ss
using all six methods, whereas 47 cryptic 5¢ss had lower scores
than their authentic 5¢ss according to all six methods.
b-Globin as an atypical model of cryptic splice-site
activation
Whereas most of the cryptic 5¢ss have signi®cantly lower S&S
consensus values than the authentic sites (63 out of 76 cases),
the b-globin cryptic 5¢ss at position ±16 of exon 1, which is
activated by several b-thalassemia mutations (16), has a
slightly higher score than the authentic 5¢ss (81.84 versus
80.10, Fig. 4A). Moreover, the distance between the two sites
is only 16 nt, which is much smaller than the absolute average
distance for the whole set of cryptic 5¢ss (63 nt, Table 2). We
chose this example for experimental analysis to try to
understand how the authentic and ±16 cryptic 5¢ss are
distinguished. We used in vitro splicing reactions with a
panel of mutant b-globin substrates and measured the relative
use of the authentic (+1) and cryptic (±16) 5¢ss.
Previous studies suggested that the cryptic 5¢ss at ±16 is
potentially defective in U1 snRNA binding (17). Other studies
showed that the use of certain 5¢ss depends on U1 binding to a
downstream sequence, which in turn facilitates binding of
U6 to the actual 5¢ss (15). To test whether splicing via the
b-globin ±16 cryptic 5¢ss depends on U1 binding to the mutant
Figure 2. Density plot of the distribution of distances between authentic
and cryptic 5¢ss. The R statistical package (http://cran.r-project.org) was
used to ®t a kernel density plot to the distances between authentic and
cryptic 5¢ss. The y-axis shows the density of cryptic 5¢ss, and the x-axis, the
distance from the cryptic to the authentic site at position +1. (a) Positive
and negative numbers correspond to cryptic splice sites located in the down-
stream intron or the upstream exon, respectively. The number of occur-
rences for each distance is shown by the blue bars at the bottom of the
display, and the corresponding scale is shown on the right side. (b) Density
of distances for exonic (blue) or intronic (red) cryptic 5¢ss. In this case, only
the absolute distances are shown.
Table 3. Statistical analysis of S&S scores for the different categories of
5¢ss
Category Average SD
A 82.96 6.31
M 65.59 8.71
C 72.38 8.53
P 68.10 4.49
AS 78.26 9.08
Comparisons by categorya
Pairs Result P
A versus M A > M <10±20
A versus C A > C <10±10
C versus M C > M <10±5
C versus P C > P 0.024
A versus P A > P <10±13
A versus AS A > AS <10±3
AS versus C AS > C <10±5
Pairwise comparisonsb
Pairs Average differencec SD P
A±M 16.40 9.20 <10±4
A±C 11.22 11.78 <10±3
C±M 7.98 13.60 <10±2
C±P 4.28 10.71 <0.19
A±P 15.87 8.00 <10±2
A, authentic 5¢ss; C, cryptic 5¢ss; M, mutant 5¢ss; P, pseudo 5¢ss; AS,
alternative 5¢ss. Gradation of 5¢ss ef®ciency: A > AS > C > M, C ~ P.
aP-values obtained using the Mann±Whitney rank test.
bP-values obtained using the Wilcoxon signed rank test.
cAverage of the differences between each pair of 5¢ss.
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5¢ss downstream, we mutated the +1 authentic 5¢ss to a
sequence whose intronic portion completely lacks comple-
mentarity to the U1 snRNA 5¢ terminus (authentic 5¢ss
changed from CAG/GTTGGT to CAG/AACCCG). Splicing
of this pre-mRNA in HeLa cell nuclear extract proceeded
through use of the ±16 cryptic 5¢ss (Fig. 4B, lane 1). However,
this site was used much less ef®ciently than in the
b-thalassemia IVS1-G1A mutant (Fig. 4A and B, lane 6).
We conclude that the ±16 5¢ss can be recognized indepen-
dently of the natural 5¢ss, although a weakÐor an inactive
but still recognizableÐ5¢ss at +1 can enhance the use of the
±16 site.
To address possible effects of the different sequence
contexts surrounding the ±16 and +1 5¢ss, we designed the
following three mutants: a duplication of the 9 nt sequence of
the +1 5¢ss, at positions ±16 and +1; a duplication of the ±16
5¢ss at the same positions; and a swap of the sequences
between the ±16 and +1 5¢ss. The ®rst mutant substrate spliced
via both +1 sequences at the two different positions, showing
no preference for the sequence context at position +1 (Fig. 4B,
lane 2). The second mutant substrate spliced only via the distal
5¢ss, suggesting that under these conditions, the context
surrounding the upstream site and/or the position itself
provides a competitive advantage (Fig. 4B, lane 3). The
swap mutant spliced only via the natural 5¢ss sequence placed
at the ±16 position, con®rming that the 9 nt sequence at +1 is
necessary and suf®cient to explain the splice-site selection
speci®city of this substrate (Fig. 4B, lane 4). Strikingly, the
overall splicing ef®ciencies of these three b-globin mutants
are strongly reduced (>10-fold), compared with the ef®cien-
cies of the wild-type and IVS1-G1A mutant b-globin
substrates (Fig. 4B, compare lanes 2±4 with lanes 5 and 6).
We conclude that the intrinsic sequence differences
between the splice site sequences at ±16 and +1 are suf®cient
to explain why the +1 site is normally selected, even though
these differences are not re¯ected in their respective S&S
consensus values.
DISCUSSION
Certain aspects of the molecular mechanisms of cryptic splice-
site activation have been previously outlined (17,18,22), and it
was previously shown in some individual cases, that the
cryptic 5¢ss had lower scores than the authentic 5¢ss (28,30,
49±54). However, the general basis for the different splicing
ef®ciencies between the authentic and cryptic 5¢ss has not
been determined because the small number of samples
analyzed previously did not allow the use of statistical tests.
Analysis of the present compilation of 76 cryptic splice sites in
46 human genes provides statistical evidence consistent with
the fact that this category of splice sites is not used in the wild-
type context. All the cryptic 5¢ss were given equal weight,
even though when activated they are used with widely
different ef®ciencies, which might be a source of bias in the
statistical comparisons. However, we are interested in de®ning
sequences that can function as 5¢ss when not out-competed by
the authentic 5¢ss, irrespective of the levels of use of such
splice sites in the mutant genes.
We found no biases in the distribution of cryptic 5¢ss in
exons versus introns, or in each of the three reading frames
(de®ned relative to that of the authentic 5¢ss), suggesting that
these parameters do not have a determining in¯uence on the
use of the cryptic splice sites. The absence of preference for
cryptic 5¢ss being in exons suggests that proximity to the
upstream 3¢ splice site does not provide a signi®cant
contextual advantage for cryptic splice-site activation, in
contrast to a previous proposal (55). Surprisingly, we detected
no bias against the use of cryptic 5¢ss involving a frameshift
with respect to the authentic 5¢ss, even though in many cases
frameshifted mRNAs are expected to trigger the nonsense-
mediated mRNA decay pathway (NMD). This pathway
speci®cally degrades mRNAs with premature-termination
codons (PTC)Ðgenerated by point mutations and/or as a
result of splicing alterations (e.g. exon skipping)Ðwhose
translation may be deleterious for the cell (56). We provide
two possible explanations for this ®nding. First, NMD usually
downregulates but does not completely eliminate mRNAs
with PTCs (56), and therefore, the activated cryptic 5¢ss that
result in frameshifting might appear to be used less ef®ciently,
but their use is still detectable. Secondly, use of some, but not
all, cryptic 5¢ss gives rise to mRNAs that appear to be resistant
to NMD. For example, it has recently been shown that aberrant
b-globin mRNAs that result from use of two cryptic 5¢ss have
different sensitivities to NMD, one of them being completely
unresponsive to this pathway (57). Likewise, use of two
cryptic 5¢ss in the C.elegans unc-73(e936) mutant gene gives
rise to NMD-resistant mRNAs (23). Understanding the
molecular basis for this resistance to NMD would help
Figure 3. Average S&S consensus values for ®ve types of 5¢ss. The different 5¢ss categories are: authentic (A), mutant (M), cryptic (C), pseudo (P) and
alternative (AS). (A) Average score (y-axis) of each category. (B) Average of the score differences between pairs of 5¢ss of each category associated with the
same exons.
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explain the detection of some of the cryptic 5¢ss included in
this compilation, and perhaps also the failure to detect other
potential cryptic 5¢ss.
The mean distance of 11 nt between cryptic and authentic
5¢ss places the typical cryptic 5¢ss close to the natural exonic±
intronic boundary, suggesting that the distance from the
authentic 5¢ss is an important constraint for cryptic splice-site
activation. However, the absolute mean distance is 65 nt,
indicating that the region where a given cryptic 5¢ss is located
can be relatively large. Furthermore, in many cases, several
alternative cryptic 5¢ss are used for a given mutant 5¢ss, even
though their S&S scores are sometimes very different. Taken
together, these ®ndings suggest that proximity to the authentic
5¢ss is an important, but not strict determinant for cryptic 5¢ss
activation. The fact that the length of the internal exons that
result from cryptic 5¢ss activation is usually maintained within
the optimal range suggests that cryptic 5¢ss activation is
subject to the usual constraints for optimal internal exon
inclusion, consistent with the exon de®nition model (43). The
distribution of 5¢ss further suggests that the competitive
advantage of the authentic over the cryptic 5¢ss is not related to
the length of the resulting exons. Furthermore, the hypothesis
that the cryptic 5¢ss are those good matches to the S&S matrix
that are located closest to the authentic site is not supported by
our statistical tests. Although distance to the authentic 5¢ss is
an important constraint, in some cases a cryptic and a pseudo
Figure 4. Analysis of cryptic 5¢ss activation in human b-globin. (A) Cryptic 5¢ss in the human b-globin gene. The diagram shows the ®rst two exons (gray
boxes) and ®rst intron (horizontal thin line) of HBB. The sequence around the ®rst intron 5¢ss is shown below the diagram. Vertical lines represent the cryptic
5¢ss, whose GT dinucleotides are underlined. The arrows indicate the cleavage/ligation sites. The phase, or position of the intron within a codon, is given in
Roman numerals, and the number in parenthesis is the relative position of the cryptic 5¢ss relative to the authentic 5¢ss at +1. The numbers above each splice
site are their S&S consensus values. The authentic (+1) and main cryptic (±16) 5¢ss are shown in red. The cryptic 5¢ss at +13 was mutated in all the constructs
(see Materials and Methods), and the cryptic 5¢ss at ±38 is used very inef®ciently. Three different b-thalassemia mutations (16) are shown below the sequence,
with the position and nucleotide substitution indicated in each case. (B) In vitro splicing analysis of b-globin substrates. Labeled pre-mRNAs were spliced in
HeLa cell nuclear extract, and the products were analyzed by electrophoresis on a denaturing polyacrylamide gel and autoradiography. Each construct is
shown as a vertical diagram above each lane, with the exons as light-blue boxes and the intron as a line. The horizontal line across exon 1 shows the position
of the main cryptic 5¢ss at position ±16. The small circles indicate the authentic (green) or mutant (red) 5¢ss, and the open red `do not' symbol denotes exten-
sive mutation of the authentic 5¢ss. The mobilities of the pre-mRNA and spliced mRNA bands are indicated by the diagrams on the left. Lane 1, the authentic
5¢ss at +1 was mutated from CAG/GTTGGT to CAG/AACCCG; lane 2, the cryptic 5¢ss at ±16 was mutated to a duplicate copy of the authentic site at +1;
lane 3, the authentic site at +1 was mutated to a duplicate copy of the cryptic 5¢ss at ±16; lane 4, the positions of the authentic site at +1 and the cryptic site
at ±16 were swapped; lane 5, wild-type pre-mRNA; lane 6, IVS1-G1A thalassemia mutation.
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5¢ss are indistinguishable with respect to their S&S scores.
Context sequences may explain the differential 5¢ss selection
in these cases. Indeed, the role of exonic splicing enhancers
(ESEs) in 5¢ss selection can be essential, and ESEs appear to
be widespread (58). Speci®c sequences within introns can also
be critical for 5¢ss selection, as demonstrated, e.g. for the
intronic G-triplets that are frequently present near 5¢ss (59).
The effect of splicing silencers, a less well de®ned category of
splicing-repressor elements (60), may explain the competitive
advantage of the cryptic over the pseudo 5¢ss in these
exceptions. Further experimental studies with speci®c sub-
strates, to address the context requirements for cryptic
splice-site activation, might prove informative.
Most importantly, the present analysis shows that in most
cases, the differences in the 9 nt long 5¢ss, measured with
the S&S matrix, are suf®cient to explain the competitive
advantage of the authentic 5¢ss versus the cryptic ones. This
difference can explain why only the former are used in wild-
type pre-mRNAs. The quantitative analysis of the 5¢ss scores
enables us to propose a gradation of 5¢ss: splice-site selection
at authentic 5¢ss is more ef®cient than at cryptic 5¢ss, which in
turn is more ef®cient than at mutated versions of the authentic
sites. As a point of reference, alternative 5¢ss have scores that
lie between those of authentic and cryptic 5¢ss, and are slightly
closer to the former. At present, we cannot predict which of
the potential splice sites located close to a mutated authentic
site will be activated, because the differences between cryptic
5¢ss and other potential nearby (pseudo) 5¢ss are subtle.
The question of how splicing can proceed with apparently
100% speci®city, given that authentic splice sites are in
competition with cryptic splice sites, remains unanswered.
The contribution of putative speci®city factorsÐproteins or
RNAsÐthat bind the pre-mRNA and are involved in splice-
site recognition, may be critical in some cases to distinguish
between authentic and cryptic or pseudo-splice sites. Studies
in our laboratory showed that the relative ef®ciencies of
utilization of the three cryptic 5¢ss in the human b-globin
intron 1 can be changed, both in vitro and in vivo, depending
on the levels of certain protein splicing factors (19±21). SF2/
ASF, the founding member of the SR protein family, favors
the use of the proximal (downstream) cryptic 5¢ss, whereas
hnRNP A1 favors the use of the distal (upstream) cryptic 5¢ss.
This effect was also observed with naturally occurring
alternative 5¢ss, suggesting interesting mechanistic and evolu-
tionary links between cryptic splice-site activation and
alternative splicing. In our study, alternative 5¢ss are an
intermediate category, with scores lower than those of
authentic 5¢ss, but higher than those of sub-optimal (cryptic,
pseudo or mutated) 5¢ss. However, this ®nding has to be
interpreted with caution, given that the pool of alternative 5¢ss
we used is heterogeneous, as re¯ected by the high SD of their
scores (Table 3). In contrast to the regulation of alternative
5¢ss, for which several speci®c proteins have been described to
in¯uence their relative use, no protein factor is so far known to
be involved in the discrimination between authentic and
cryptic splice sites in a wild-type context. Alternatively, the
NMD pathway might eliminate low levels of aberrant splicing
arising from leaky use of certain cryptic 5¢ss in a wild-type
pre-mRNA, although this scenario remains hypothetical.
Consistent with the models of `exon de®nition' (43) and
`multiple weak interactions' (61), exons whose 5¢ss is
disrupted by a mutation are either skipped during pre-
mRNA splicing or included (at least partially) by using a
cryptic 5¢ss. Indeed, intermediate cases in which both
pathways work alternatively are frequent. We suggest that
inactivation of the 5¢ss of an exon should result in exon
skipping when the overall signals that de®ne this sequence as
an exon become sub-optimal as a result of the mutation, as
proposed earlier (55). In contrast, exons associated with a 5¢ss
mutation that are included (at least in part) by utilizing a
cryptic 5¢ss still have a `splicing-favorable' context; thus,
other splicing signals, such as the 3¢ splice site and the ESEs,
are suf®cient to specify this pre-mRNA segment as an exon.
Such a context allows a sub-optimal, neighboring 5¢ssÐthe
Table 4. Comparison of authentic and cryptic 5¢ss using different scoring
methods
MAXENTa MDDb MMc S&Sd NNe DGf
Average (A) 8.16 12.45 7.78 82.96 0.84 ±10.8
SD (A) 1.94 1.84 1.86 6.31 0.24 2
Average (C) 3.18 7.99 4.12 72.38 0.33 ±8.6
SD (C) 4.89 3.65 3.45 8.53 0.36 2.9
Average (A±C) 4.98 4.46 3.66 11.22 0.52 ±2.4
SD (A±C) 5.61 4.23 4.37 11.78 0.39 3.9
Exceptionsg,h
ABCD1 exon 1 + +
AR exon 4 +
BRCA1 exon 5 +
BRCA1 exon 16 +
COL1A1 exon 8 (1) + + + + + +
COL1A1 exon 8 (2) + + + + + +
COL3A1 exon 42 +
COL7A1 exon 3 +
CYP19 exon 6 + + + + +
CYP27A1 exon 6 + +
DMD exon 64 + +
FAH exon 12 +
GHV exon 2 + + + +
HBA2 exon 1 +
HBB exon 1 (2) +
HEXA exon 9 + + + +
HPRT1 exon 1 +
HPRT1 exon 5 + + + + + +
IDS exon 7 + + + +
ITGB2 exon 7 (1) +
ITGB2 exon 7 (2) +
ITGB3 exon 4 + +
LPL exon 2 (3) +
LPL exon 2 (4) +
NF1 exon 28 +
NF2 exon 7 (2) +
PGK1 exon 4 +
PTEN exon 7 + +
PYGM exon 14 + +
Total 8 6 9 13 6 21
A, authentic 5¢ss; C, cryptic 5¢ss.
aMaximum entropy model.
bMaximum dependence decomposition model.
cFirst-order Markov model.
dShapiro and Senapathy matrix.
eNeural network.
fStability of the RNA duplex between the 5¢ss and the U1 snRNA 5¢
terminus.
gThe exceptions (+) are those in which the cryptic 5¢ss has a higher score
than the corresponding authentic 5¢ss.
hIf there is more than one cryptic 5¢ss for a particular exon, it is indicated
by the number in parenthesis, in the order shown in Table 1.
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cryptic splice siteÐto be used. The threshold of signals that
de®nes a sequence as an exon is still largely unknown because
of our incomplete knowledge of all the relevant elements and
their relative contributions to exon de®nition.
Comparison of most of the pairs of authentic and cryptic
5¢ss shows signi®cant differences in their S&S scores, which
can explain why the correct splice sites are selected. There are
a few exceptions to this trend, such as the example of human
b-globin exon 1. Both in vivo and in vitro splicing experiments
with b-globin pre-mRNA have shown that the cryptic 5¢ss at
±16, although it is close to, and has a higher score than, the
correct splice site (at +1), is never used in the wild-type
context (16,19,62). However, the authentic 5¢ss at +1 has
seven potential Watson±Crick base pairs plus one wobble base
pair to the U1 snRNA 5¢ terminus, whereas the cryptic 5¢ss at
±16 has only ®ve Watson±Crick plus one wobble base pair to
U1. The calculated free-energy parameters (±14 kcal/mol for
+1 versus ±9.9 kcal/mol for ±16) are also consistent with a
greater base-pairing potential of the +1 site to U1 snRNA.
Thus, this exception could be attributable to a limitation of the
S&S algorithm, which in this case does not re¯ect the intrinsic
differences in ef®ciency between 5¢ss at +1 (authentic 5¢ss)
and ±16 (major cryptic 5¢ss). For instance, one of the
limitations of the S&S matrix is that it assumes independence
between each of the nine positions. However, dependencies
between each of the consensus positions are likely to exist, e.g.
due to nearest-neighbor effects on RNA base-pairing stability.
We have also shown that the lack of splicing via the 5¢ss at ±16
in the wild-type pre-mRNA is not due to the relative position
of this splice site, or to its local sequence context, but rather to
intrinsic differences between the cryptic and the competing
authentic 5¢ss. The results with both duplication mutants
(Fig. 4B, lanes 2 and 3) suggest that splicing via the ±16 5¢ss
sequence, but not the +1 sequence, can only take place at its
natural position at ±16, which could be due to its proximity to
the 5¢ cap structure. On the other hand, the ±16 cryptic 5¢ss is
not intrinsically defective, because it can function in the
context of an inactive or debilitated site at +1, and moreover,
identical 9 nt sequences function as normal 5¢ss in other genes
(such as the authentic 5¢ss of exon 48 in the human COL1A1
gene). Our ®ndings thus far do not account for the remarkable
®delity of the splicing reaction, i.e. they do not explain why
use of the ±16 5¢ss is undetectable in the wild-type b-globin
context.
All the new b-globin mutant substrates tested in this study
show reduced splicing ef®ciency (Fig. 4B). Thus, these
mutations could reduce splice-site recognition at both 5¢ss or
affect a subsequent step of the splicing reaction. One possible
explanation for this phenomenon is that these mutations could
affect the overall secondary structure of the b-globin pre-
mRNA, thereby compromising the ef®ciency of the reaction.
Alternatively, simultaneous assembly of splicing factors at
nearby 5¢ss could result in steric hindrance effects that may
account for the reduced overall splicing ef®ciency of these
mutants (12,63). The latter hypothesis would explain the
reduced ef®ciency of both duplication mutants (Fig. 4B, lanes
2 and 3). However, the high splicing ef®ciencies of b-globin
substrates bearing IVS1-G5C or T6C mutations (16), which
result in splicing via both +1 and ±16 5¢ss, argue against a
steric hindrance model. The reduced ef®ciency of the mutant
with swapped sequences between the ±16 and +1 5¢ss (Fig. 4B,
lane 4) also suggests that the inef®cient splicing at position
±16 is not speci®c to the sequence of the cryptic 5¢ss at ±16.
Furthermore, the +1 5¢ss mutant G1A (16), shown in lane 6 of
Figure 4B, splices very ef®ciently via the ±16 5¢ss. Taken
together, these results suggest that ef®cient splicing requires
an optimal context, present only in the wild-type and single
mutant substrates, and this context is disrupted by all tested
extensive mutations of any of these 5¢ss sequences.
Interestingly, the analysis of the strength of base pairing
between the different categories of 5¢ss and U1 snRNA
revealed that 21 cryptic 5¢ss have a stronger base-pairing
potential than their corresponding authentic 5¢ss, whereas only
13 cryptic 5¢ss have higher S&S scores than their correspond-
ing authentic 5¢ss. In addition, nine of these exceptions were
found by both methods. Thus, the S&S matrix appears to be a
better heuristic discriminator between the different categories
of 5¢ss than the calculated stability of the 5¢ss-U1 snRNA
duplex. This observation suggests that stronger base pairing of
authentic 5¢ss to U1 snRNA may not be the general feature that
distinguishes authentic and cryptic 5¢ss, but rather other
intrinsic sequence patterns within the consensus 5¢ss
sequenceÐsomehow implicit in the S&S matrixÐmay con-
tribute to the correct discrimination between these two
categories of 5¢ss. Another possibility, which remains to be
tested, is that the sequences surrounding the 5¢ss can play a
pivotal role in discriminating between the authentic and the
cryptic 5¢ss, similar to what we proposed above for the
discrimination between cryptic and pseudo 5¢ss.
We also analyzed the scores of authentic and cryptic 5¢ss
using four other methods (Table 4), and compared them with
the S&S scores and the free-energy parameters. These four
new matrices are, at least to some extent, better discriminators
between these 5¢ss, but the combination of exceptions suggests
that none of these methods is suf®ciently reliable: for instance,
out of the six exceptions found using the NN and six using the
MDD methods, only three were found by both. However, we
believe that the sample size in this study is not large enough to
accurately compare the reliability of these 5¢ss scoring
methods. All the methods gave the same relative ranking of
authentic > alternative > cryptic > mutant 5¢ss (data not
shown). We did not calculate pseudo splice sites by the other
methods because the threshold chosen for calculations by one
method tends to give very low cut-offs for the other ones.
Accurate prediction of the splicing patterns that result from
a mutation, as well as of the structural and functional
consequences for the corresponding protein, will help to
understand allele-speci®c differences in various diseases.
Furthermore, therapeutic approaches to correct splicing
defects relate to cryptic splice-site activation. For instance,
Dominski and Kole have used an antisense approach to
suppress the use of a cryptic 5¢ss and thereby rescue a mutant
5¢ss (64). The present study and further evaluation of cryptic
5¢ss activation will be helpful in the application of such
techniques for the treatment of diseases caused by splice-site
mutations.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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